Mark Sard
Founder chez Frontier Equities VC LLC
Profil
Mark Sard is the founder.
He founded Frontier Equities VC LLC in 2011 as a Principal.
He is currently working as a Director at Lirum Therapeutics, Inc. since 2022.
Previously, he worked as a Director at Stemline Therapeutics, Inc. from 2018 to 2020.
Mr. Sard completed his undergraduate degree at the University of Pennsylvania.
Postes actifs de Mark Sard
| Sociétés | Poste | Début |
|---|---|---|
Frontier Equities VC LLC
 Frontier Equities VC LLC Investment ManagersFinance Frontier Equities VC LLC (Frontier Equities) is a venture capital firm founded in 2011 by Mark Sard. The firm is headquartered in New York, United States. | Founder | 01/01/2011 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 01/11/2022 |
Anciens postes connus de Mark Sard
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Director/Board Member | 10/06/2020 |
Formation de Mark Sard
| University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
 | Health Technology |
| Entreprise privées | 2 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Frontier Equities VC LLC
Frontier Equities VC LLC Investment ManagersFinance Frontier Equities VC LLC (Frontier Equities) is a venture capital firm founded in 2011 by Mark Sard. The firm is headquartered in New York, United States. | Finance |
